Director at Bristol Myers (NYSE: BMY) gains 3,996 deferred units

Rhea-AI Filing Summary

Bristol Myers Squibb director Michael R. McMullen reported an acquisition of 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 per unit. Following this transaction, he beneficially owns 14,979.689 Deferred Share Units directly.

Each Deferred Share Unit will convert into one share of common stock upon settlement, which occurs when McMullen ceases to be a director or at a future date he previously specified. The reported holdings include deferred compensation and dividends reinvested under the company’s 1987 Deferred Compensation Plan for Non-Employee Directors.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider McMullen Michael R.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Deferred Share Units	3,996.367	$55.05	$220K

Holdings After Transaction: Deferred Share Units — 14,979.689 shares (Direct)

Footnotes (1)

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

McMullen Michael R.

(Last) (First) (Middle)

BRISTOL-MYERS SQUIBB COMPANY

ROUTE 206 AND PROVINCE LINE ROAD

(Street)

PRINCETON NJ 08543

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BRISTOL MYERS SQUIBB CO [ BMY ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
02/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Deferred Share Units	(1)	02/01/2026		A		3,996.367		(1)	(1)	Common Stock, $0.10 par value	3,996.367	$55.05	14,979.689(2)	D

Explanation of Responses:

1. Each Deferred Share Unit will be converted into a share of common stock upon settlement. The Deferred Share Units become settleable when the reporting person ceases to be a director or at a future date previously specified by the reporting person.

2. Includes deferred compensation and dividends reinvested under the 1987 Deferred Compensation Plan for Non-Employee Directors.

Remarks:

	/s/ Amy Fallone, attorney-in-fact for Michael R. McMullen	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did BMY director Michael R. McMullen report?

Michael R. McMullen reported acquiring 3,996.367 Deferred Share Units on February 1, 2026 at $55.05 each. These units are part of a deferred compensation arrangement and increase his directly held Deferred Share Units to 14,979.689 after the transaction.

How many Deferred Share Units does Michael R. McMullen hold in Bristol Myers Squibb (BMY) after this Form 4?

After the reported transaction, Michael R. McMullen beneficially owns 14,979.689 Deferred Share Units directly. This total reflects the newly acquired 3,996.367 units plus prior holdings, including amounts tied to deferred compensation and dividends reinvested under the company’s non‑employee director plan.

At what price were the new Bristol Myers Squibb (BMY) Deferred Share Units acquired?

The newly reported 3,996.367 Deferred Share Units were acquired at $55.05 per unit. This price applies to the derivative security, which represents the right to receive shares of Bristol Myers Squibb common stock upon future settlement under the director compensation program.

When will Michael R. McMullen’s Deferred Share Units in BMY convert into common stock?

Each Deferred Share Unit will convert into one share of common stock upon settlement. Settlement occurs when McMullen ceases to be a director or on a future date he previously specified, according to the terms of Bristol Myers Squibb’s non‑employee director deferred compensation plan.

What plan covers the Deferred Share Units reported by BMY director Michael R. McMullen?

The Deferred Share Units are associated with Bristol Myers Squibb’s 1987 Deferred Compensation Plan for Non‑Employee Directors. His reported holdings include deferred compensation amounts and dividends that have been reinvested under this plan, which provides equity-linked compensation instead of immediate cash.

Is Michael R. McMullen’s ownership of Bristol Myers Squibb (BMY) Deferred Share Units direct or indirect?

The filing shows Michael R. McMullen’s 14,979.689 Deferred Share Units as directly owned. The ownership form is marked as “D” for direct, and no footnotes state that the units are held through a separate trust, partnership, or other indirect entity.